Table 3. Clinical and functional characteristics of the IPF patients according to the detection of fibrocytes in BAL.

	Fibrocytes(+)	Fibrocytes(−)	P value
Number of patients (%)	14 (54%)	12 (46%)
Age	73 [56–83]	75 [65–84]	0.49
Gender (Male)	12 (85%)	7 (58%)	0.12
Smoker (ever)	9 (64%)	7 (58%)	1
Exacerbation	1 (7%)	2 (28%)	0.58
Delay since diagnosis (days)	13 [0–655]	17 [0–250]	0.45
Oral steroids	3 (21%)	3 (25%)	1
Death or lung transplant	6	4	0.7
Pulmonary Hypertension (N)	0	3	0.08
HRCT fibrosis score	8 [4]–[14]	8 [6]–[13]	0.98
Fibrocyte count/ml	5240 [369–29550]	0 [0–0]
CCL2 (pg/ml)	106 [0–350]	182 [11–1033]	0.14
CXCL12 (pg/ml)	0 [0–0]	0 [0–22.7]	0.37
Lung function tests
VC (% pred)	79 [34–108]	70 [40–96]	0.7
DLCO (% pred)	45 [15–91]	45 [58–73]	0.06
PaO2 (mm Hg)	78 [45–101]	76 [59–92]	0.48

Data are expressed as median [range] or N (%).